CGEN - Compugen Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.2500
-0.0500 (-1.52%)
As of 11:10AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.3000
Open3.2500
Bid3.26 x 900
Ask3.29 x 800
Day's Range3.2500 - 3.2900
52 Week Range2.3500 - 5.0000
Volume46,342
Avg. Volume212,158
Market Cap185.89M
Beta (3Y Monthly)1.53
PE Ratio (TTM)N/A
EPS (TTM)-0.42
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Trade prices are not sourced from all markets
  • GlobeNewswire17 days ago

    New Research Coverage Highlights Vulcan Materials, Cimpress N.V, Asterias Biotherapeutics, ElectraMeccanica Vehicles, Compugen, and China HGS Real Estate — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire27 days ago

    Compugen Announces Issuance of U.S. Patent for COM902, Its TIGIT Antibody Product Candidate for Cancer Immunotherapy

    HOLON, Israel, Nov. 13, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that a patent for COM902, the Company's TIGIT therapeutic antibody candidate, has been issued by the United States Patent and Trademark Office (USPTO) under the USPTO's Cancer Moonshot Pilot Program providing early examination of patent applications pertaining to cancer immunotherapy. Activating T cells results in stimulating the immune system, and therefore could be used for cancer immunotherapy treatment. This patent as well as other patents the Company is pursuing for COM902 are part of its global patent strategy covering its innovative immuno-oncology pipeline.

  • Compugen (CGEN) Reports Q3 Loss
    Zackslast month

    Compugen (CGEN) Reports Q3 Loss

    Compugen (CGEN) delivered earnings and revenue surprises of 58.33% and 0.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Compugen: 3Q Earnings Snapshot

    The Holon, Israel-based company said it had a loss of 5 cents per share. The drug developer posted revenue of $7.8 million in the period. The company's shares closed at $3.08. A year ago, they were trading ...

  • PR Newswirelast month

    Compugen Reports Third Quarter 2018 Results

    HOLON, Israel , Nov. 7, 2018 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for ...

  • Compugen Ltd. (CGEN) Sees Hammer Chart Pattern: Time to Buy?
    Zackslast month

    Compugen Ltd. (CGEN) Sees Hammer Chart Pattern: Time to Buy?

    Compugen has been struggling lately, but the selling pressure may be coming to an end soon.

  • PR Newswire2 months ago

    Compugen Third Quarter 2018 Conference Call Scheduled for Wednesday, November 7, 2018 at 8:30 AM ET

    HOLON, Israel , Oct. 24, 2018 /PRNewswire/ --  Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company ...

  • Benzinga2 months ago

    Don't Fixate On Market Woes, Just Make Your Trades

    Beyond my recent losses, October has actually been a strong month for me, although some in the chat are wondering how the recent market-wide selloff is affecting day traders. It was a fairly typical day for me, I was up, then down, then up again. Two of the top stocks to appear on my premarket scanner on Thursday, Spherix Inc. (NASDAQ: SPEX) and Compugen Ltd. (NASDAQ: CGEN), both collapsed on the opening bell.

  • Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal
    Zacks2 months ago

    Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal

    AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.

  • Bristol-Myers Inks Deal and Invests $12 Million in Compugen
    Zacks2 months ago

    Bristol-Myers Inks Deal and Invests $12 Million in Compugen

    Bristol-Myers (BMY) enters a clinical trial collaboration with Compugen and will make a $12-million equity investment in the latter.

  • MarketWatch2 months ago

    Compugen's stock shoots up after Bristol-Myers to pay 52% premium for equity stake

    Shares of Compugen Ltd. shot up 17% in premarket trade Thursday, after Bristol-Myers Squibb Co. said it will make a $12 million equity investment as part of a collaboration on a cancer treatment. As part of the agreement, Bristol-Myers will buy about 2.4 million shares at $4.95 a share, which is 52% above Wednesday's closing price of $3.25. The companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen's investigational anti-PVRIG antibody, COM701, in combination with Bristol-Myers' immune checkpoint inhibitor Opdivo, in patients with advanced solid tumors. Bristol-Myers' stock fell 1.3% ahead of the open. Year to date, Compugen's stock has soared 30% through Wednesday, while Bristol-Myers shares have slipped 0.8% and the S&P 500 has gained 4.2%.

  • Reuters2 months ago

    Bristol-Myers to invest in Compugen, collaborate in clinical trials

    Bristol-Myers Squibb Co and Israel's Compugen said on Thursday they will collaborate in clinical trials for patients with advanced solid tumours. The trials will evaluate the safety and tolerability of Compugen’s COM701, an investigational antibody, in combination with Bristol-Myers Squibb’s immune checkpoint inhibitor Opdivo. In conjunction with the collaboration, Bristol-Myers Squibb will invest $12 million in Compugen, purchasing 2,424,243 shares - equal to a 4.1 percent stake - at $4.95 each.

  • PR Newswire2 months ago

    Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors

    NEW YORK and HOLON, Israel , Oct. 11, 2018 /PRNewswire/ --  Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration ...

  • Business Wire2 months ago

    Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors

    Bristol-Myers Squibb Company and Compugen today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen’s COM701, an investigational anti-PVRIG antibody, in combination with Bristol-Myers Squibb’s programmed death-1 immune checkpoint inhibitor Opdivo , in patients with advanced solid tumors.

  • PR Newswire3 months ago

    Compugen Announces Clinical Milestone Payment in Cancer Immunotherapy Collaboration With Bayer Following Dosing of First Patient in BAY 1905254 Phase 1 Trial

    HOLON, Israel, Sept. 20, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, was informed that Bayer AG dosed the first patient in the Phase 1 clinical trial of BAY 1905254, a first-in-class immuno-oncology therapeutic antibody targeting the ILDR2 protein, in patients with advanced solid tumors.  Under the terms of the collaboration and license agreement, Compugen is entitled to a milestone payment of $7.8 million at first patient dosing.

  • Should You Have Compugen Ltd’s (NASDAQ:CGEN) In Your Portfolio?
    Simply Wall St.3 months ago

    Should You Have Compugen Ltd’s (NASDAQ:CGEN) In Your Portfolio?

    Anyone researching Compugen Ltd (NASDAQ:CGEN) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there areRead More...

  • PR Newswire3 months ago

    Compugen Announces First Patient Dosed with COM701, a First-in-Class Cancer Immunotherapy Antibody, in Phase 1 Clinical Trial

    HOLON, Israel, Sept. 7, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in its Phase 1 clinical trial of COM701, a first-in-class cancer immunotherapy antibody targeting PVRIG. PVRIG is a novel immune checkpoint identified by Compugen using its computational discovery capabilities. "Dosing the first patient with COM701, a first-in-class drug opportunity targeting a novel immune checkpoint we identified with our computational predictive platform, is a landmark event for us.

  • PR Newswire3 months ago

    Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors

    HOLON, Israel, Sept. 5, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the appointment of Jean-Pierre Bizzari, M.D., formerly Executive Vice President and Global Head of Oncology at Celgene Corporation, to its Board of Directors. "I am delighted to welcome Jean-Pierre to Compugen's Board," said Paul Sekhri, Chairman of the Board. "I am confident that his extensive experience in oncology drug development will prove invaluable to Compugen.

  • Associated Press4 months ago

    Compugen: 2Q Earnings Snapshot

    The Holon, Israel-based company said it had a loss of 19 cents per share. The company's shares closed at $3.15. A year ago, they were trading at $4.05. _____ This story was generated by Automated Insights ...

  • PR Newswire4 months ago

    Compugen Reports Second Quarter 2018 Results

    Preparations for first patient dosing on track to take place in early fall HOLON, ISRAEL , Aug 1, 2018 /PRNewswire/ -- Compugen Ltd. ( Nasdaq: CGEN ), a clinical-stage cancer immunotherapy company and ...

  • ACCESSWIRE4 months ago

    Compugen Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 1, 2018 / Compugen Ltd. (NASDAQ: CGEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 1, 2018 at 8:30 AM Eastern Time. To listen ...

  • PR Newswire5 months ago

    Compugen Second Quarter 2018 Conference Call Scheduled for Wednesday, August 1, 2018 at 8:30 AM ET

    HOLON, Israel , July 18, 2018 /PRNewswire/ --  Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company ...

  • Benzinga5 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Alkermes Plc (NASDAQ: ALKS ) stock was trading higher ...

  • PR Newswire5 months ago

    Compugen Welcomes FDA Clearance of Bayer's IND Application for BAY 1905254

    HOLON, Israel, July 2, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN) (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, was informed that the U.S. Food and Drug Administration (FDA) has cleared Bayer AG's investigational new drug (IND) application for BAY 1905254, a first-in-class immuno-oncology therapeutic antibody targeting the ILDR2 protein in patients with advanced solid tumors. ILDR2 is a novel immune checkpoint discovered by Compugen through its predictive computational capabilities, which enable the discovery of new drug targets and biological pathways.

  • PR Newswire5 months ago

    Compugen Announces FDA Clearance of IND Application for COM701, a First-in-class Immuno-Oncology Therapeutic Antibody

    Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on its investigational new drug (IND) application for COM701, a first-in-class immuno-oncology therapeutic antibody targeting PVRIG in patients with advanced solid tumors, and informed the Company it may initiate the clinical study. "Today is a significant milestone for Compugen, having received clearance from the FDA to advance our lead immuno-oncology program into the clinic. COM701 is a first-in-class drug opportunity that was developed by Compugen from discovery of the drug target by computer prediction through preclinical development, to IND clearance," stated Anat Cohen-Dayag, PhD, President and CEO of Compugen.